Oramed Pharmaceuticals Inc (ORMP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $169.59M
Last updated: Nov 17, 2026 at 4:15 PM ET
Oramed Pharmaceuticals Inc (ORMP) Stock Chart
Oramed Pharmaceuticals (ORMP) has a latest price of $3.87 on Nov 17, 2026, 29.3% below its 52-week high of $5.47. Its price rose 77.4% over the past 12 months. The month-end price fell 38.1% over the 10 years through Oct 2026, a compound annual decline of 4.7%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $23.41 in Oct 2021 and its lowest $1.83 in Oct 2023, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart ORMP with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for ORMP.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 19.2%, and over 6 months it fell 10.6%. The month-end price rose 124.6% over the 3 years through Oct 2026, a compound annual rate of 31.0%.
| Period | Change |
|---|---|
| 1 month | -4.7% |
| 3 months | -19.2% |
| 6 months | -10.6% |
| 12 months | +77.4% |
| 12 months, with dividends | +88.8% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +124.6% | +31.0% |
| 5 years | -82.4% | -29.4% |
| 10 years | -38.1% | -4.7% |
Price by Year
Its best calendar year was 2021, when the price rose 236.8%, and its weakest was 2023, when it fell 80.8%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $4.11 | +44.2% |
| 2025 | $2.85 | +17.8% |
| 2024 | $2.42 | +4.8% |
| 2023 | $2.31 | -80.8% |
| 2022 | $12.03 | -15.8% |
| 2021 | $14.28 | +236.8% |
| 2020 | $4.24 | -17.7% |
| 2019 | $5.15 | +71.7% |
| 2018 | $3.00 | -66.7% |
| 2017 | $9.00 | +47.1% |
Trading Range
The price is 10.3% below its 50-day average of $4.32 and 4.7% below its 200-day average of $4.06.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $3.87 | |
| 52-week high | $5.47 | -29.3% |
| 52-week low | $2.22 | +74.4% |
| 50-day average | $4.32 | -10.3% |
| 200-day average | $4.06 | -4.7% |
Price Risk
Over 3 years, its largest fall from a peak was 44.1%.
| Measure | Value |
|---|---|
| 1-year beta | 1.18 |
| Largest fall, 1 year | -30.5% |
| Largest fall, 3 years | -44.1% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About ORMP
What is ORMP's 1-year price change?
Oramed Pharmaceuticals's price rose 77.4% over the past 12 months. With dividends included, the 12-month total return was 88.8%.
What is ORMP's 5-year price change?
Oramed Pharmaceuticals's month-end price fell 82.4% over the 5 years through Oct 2026, a compound annual decline of 29.4%. These figures leave out dividends.
What is ORMP's 52-week high and low?
Oramed Pharmaceuticals's 52-week high is $5.47 and its 52-week low is $2.22. Its latest price of $3.87 on Nov 17, 2026 is 29.3% below the high.
What is ORMP's beta?
Oramed Pharmaceuticals's 1-year beta against the S&P 500 is 1.18, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 30.5%.
Is the ORMP chart free?
Yes. Advanced Charting for ORMP is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
ORMP pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors